Last reviewed · How we verify
E. Coli Osteomyelitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Tobi · Novartis
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
- Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Rocephin · Generic (originally Roche)
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- E. Coli Osteomyelitis patent landscape — cliff calendar, originator estates, attackable patents
- E. Coli Osteomyelitis treatment landscape brief
- E. Coli Osteomyelitis treatment updates RSS
Frequently asked questions about E. Coli Osteomyelitis
What drugs treat E. Coli Osteomyelitis?
Tracked treatments include Ramycin, Tobi, Vantobra, Nebcin, Ceftriaxon, Rocephin.
What is the treatment for E. Coli Osteomyelitis?
Standard treatment for E. Coli Osteomyelitis includes Ramycin, Tobi, Vantobra, Nebcin, Ceftriaxon. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: E. Coli Osteomyelitis patent cliff · E. Coli Osteomyelitis CI report
- Treatment: Ramycin
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Nebcin · University Hospital, Lille
- Treatment: Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing